Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

29.22
BATS BZX Real-Time Price
As of 9:57am ET
 +2.28 / +8.46%
Today’s Change
23.55
Today|||52-Week Range
263.81
-71.25%
Year-to-Date
Analysts Differ On Impact Of Valeant's Rejected Takeover Bid
10:48am / TheStreet.com - Paid Partner Content
European Stocks Mixed as Oil, Chinese Benchmarks Fall
6:30am / TheStreet.com - Paid Partner Content
Valeant (VRX) Stock Surges on Rejected Takeda, TPG Bid Speculation
9:14am / TheStreet.com - Paid Partner Content
Valeant 'Received Bid Proposal' From Takeda, TPG
6:30am / TheStreet.com - Paid Partner Content
First-Quarter GDP Revised Upward; Futures Indicate Higher Opening
9:00am / TheStreet.com - Paid Partner Content
May 27 Premarket Briefing: 10 Things You Should Know
6:30am / TheStreet.com - Paid Partner Content
Frontrunning: May 27
8:07am / Investing Channel - Paid Partner Content
Wally Weitz Sells Plunging Drug Stock Endo but Thinks It Has 'Upside Potential'
May 26 / GuruFocus News - Paid Partner Content
All Eyes On Yellen: Global Markets Flat On Dreadful Volumes, Oil Slides
7:17am / Investing Channel - Paid Partner Content
Valeant Works to Restore Accounting Reputation
May 26 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close26.94
Today’s open28.19
Day’s range27.85 - 29.40
Volume362,650
Average volume (3 months)26,477,301
Market cap$9.2B
Dividend yield--
Data as of 9:57am ET, 05/27/2016

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-16.58%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book1.56

Competitors

 Today’s
change
Today’s
% change
JAZZJazz Pharmaceuticals...+0.84+0.55%
MDVNMedivation Inc+0.02+0.03%
IDXXIDEXX Laboratories I...+0.20+0.22%
RDYDr.Reddy's Laborator...+0.76+1.66%
Data as of 10:56am ET, 05/27/2016

Financials

Next reporting dateJune 10, 2016
EPS forecast (this quarter)$1.36
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer, Director &
Executive VP
Robert L. Rosiello
Corporate headquarters
Laval, Quă©bec

Forecasts

Partner Offers

Search for Jobs